Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Liver International · 2025
DOI: 10.1111/liv.16174 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Liver International, 2025. Verfasst von Tarik Asselah und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Inc., Gilead Sciences.
Abstract (Originalsprache)
Background and Aims The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients with chronic hepatitis delta (CHD).
Methods
Week 48 on‐treatment clinical and laboratory results from two Phase 2 trials (MYR203 [NCT02888106] and MYR204 [NCT03852433]) and one Phase 3 trial (MYR301 [NCT03852719]) were pooled ( N = 269). Patients were grouped as follows: BLV 2 mg ( n = 64), BLV 10 mg ( n = 115), pegylated interferon‐alfa ( n = 39) and control ( n = 51). The control group consisted of patients assigned to the delayed treatment group in Study MYR301.
Results
Adverse events (AEs) that occurred more frequently with BLV 2 mg and BLV 10 mg versus control included increased total bile acid levels (20% and 17% vs. 0%), injection‐site reactions (16% and 20% vs. 0%), headache (16% and 17% vs. 0%), pruritus (11% and 10% vs. 0%) and eosinophilia (9% and 4% vs. 0%). Increases in total bile acid levels were observed with BLV without clear correlation with AEs, such as pruritus, eosinophilia or vitamin D deficiency. Grade 3 or 4 study drug–related AEs occurred in a higher proportion of patients receiving pegylated interferon‐alfa (51%) than with BLV 2 or 10 mg (3% and 4%, respectively). There were no serious AEs related to BLV, and no patients discontinued BLV due to an AE. Neither hepatic decompensation nor death occurred.
Conclusions
BLV monotherapy was safe and well tolerated through 48 weeks of treatment in patients with CHD. Trial Registration: NCT02888106, NCT03852433 and NCT03852719
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- CRC 'A. M. And A. Migliavacca' Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
- Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden.
- Hôpital Saint Joseph, Marseille, France.
- National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania.
ORCID-Profile: Tarik Asselah, Pietro Lampertico, Dmitry Manuilov, Maurizia R Brunetto, Heiner Wedemeyer
Förderung
- Gilead Sciences Inc.
- Gilead Sciences
Zitieren
APA
Asselah, T., Lampertico, P., Aleman, S., Bourlière, M., Streinu-Cercel, A., Bogomolov, P., Morozov, V., Stepanova, T., Lazar, S., Manuilov, D., Mercier, R. C., Tseng, S., Ye, L., Flaherty, J. F., Osinusi, A., Da, B. L., Chee, G. M., Lau, A. H., Brunetto, M. R., & Wedemeyer, H. (2025). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. https://doi.org/10.1111/liv.16174
Vancouver
Asselah T, Lampertico P, Aleman S, Bourlière M, Streinu-Cercel A, Bogomolov P, et al. Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. 2025. doi:10.1111/liv.16174
BibTeX
@article{Asselah2025,
author = {Asselah, Tarik and Lampertico, Pietro and Aleman, Soo and Bourlière, Marc and Streinu-Cercel, Adrian and Bogomolov, Pavel and Morozov, Viacheslav and Stepanova, Tatiana and Lazar, Stefan and Manuilov, Dmitry and Mercier, Renee-Claude and Tseng, Steve and Ye, Lei and Flaherty, John F and Osinusi, Anu and Da, Ben L and Chee, Grace M and Lau, Audrey H and Brunetto, Maurizia R and Wedemeyer, Heiner},
title = {Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.16174}
}
EUVIMED